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A B S T R A C T   
Up to 80% of cancer patients are affected by the cancer anorexia-cachexia syndrome (CACS), which leads to 
excessive body weight loss, reduced treatment success and increased lethality. The area postrema/nucleus of the 
solitary tract (AP/NTS) region emerged as a central nervous key structure in this multi-factorial process. Neurons 
in this area are targeted by cytokines and signal to downstream sites involved in energy homeostasis. NTS 
neurons expressing prolactin-releasing peptide (PrRP) are implicated in the control of energy intake and 
hypothalamus-pituitary-adrenal (HPA) axis activation, which contributes to muscle wasting. To explore if 
brainstem PrRP neurons contribute to CACS, we selectively knocked down PrRP expression in the NTS of hep-
atoma tumor-bearing rats by an AAV/shRNA gene silencing approach. PrRP knockdown reduced body weight 
loss and anorexia compared to tumor-bearing controls treated with a non-silencing AAV. Gastrocnemius and total 
hind limb muscle weight was higher in PrPR knockdown rats. Corticosterone levels were increased in the early 
phase after tumor induction at day 6 in both groups but returned to baseline levels at day 21 in the PrRP 
knockdown group. While we did not detect significant changes in gene expression of markers for muscle protein 
metabolism (MuRF-1, myostatin, mTOR and REDD1), mTOR and REDD1 tended to be lower after disruption 
PrRP signalling. In conclusion, we identified brainstem PrRP as a possible neuropeptide mediator of CACS in 
hepatoma tumor-bearing rats. The central and peripheral downstream mechanisms require further investigation 
and might involve HPA axis activation.   
1. Introduction 
The cancer anorexia-cachexia syndrome (CACS) is a severe wasting 
disorder caused by an ongoing and involuntary loss of body weight that 
cannot be fully reversed by conventional nutritional support. Charac-
terized by loss of appetite (anorexia), skeletal muscle mass and adipose 
tissue (cachexia), this multifactorial syndrome is a major health concern. 
Depending on the type of cancer, up to 80% of patients in an advanced 
stage of cancer suffer from CACS (Gullett et al., 2011; Sadeghi et al., 
2018). The clinical management of CACS continues to be limited 
because no drugs have been specifically approved for the treatment of 
CACS (Sadeghi et al., 2018). An increase in cytokines (e.g. TNF-α, in-
terleukins, growth differentiation factor 15, etc.) plays a role for most of 
the underlying pathological mechanisms. Cytokines released from cells 
of the immune system or by the tumor itself act on the brain and in 
peripheral tissues to induce anorexia as well as endocrine and metabolic 
dysfunction (Langhans, 2004; Mcnamara et al., 1992). The area post-
rema/nucleus of the solitary tract (AP/NTS) region located in the caudal 
hindbrain plays a pivotal role as a target area for humoral mediators of 
CACS. Not only the AP but also part of the NTS lack a functional 
blood-brain-barrier (Broadwell and Sofroniew, 1993), which makes 
neurons in these areas accessible by blood-borne signalling molecules. 
The AP/NTS region mediates physiological satiation induced by the 
satiation hormones amylin and CCK leading to an inhibition of energy 
intake (see (Riediger, 2012; Lutz, 2010) for review). AP-lesioned rats are 
partly protected against CACS (Borner et al., 2017) and TNF-α-induced 
anorexia (Bernstein et al., 1991). We recently identified the brainstem 
neuropeptide GLP-1 (glucagon-like peptide-1) as mediator of CACS. 
Pharmacological and genetic disruption of hinbrain GLP-1 signalling 
attenuated anorexia and cachectic body weight loss in hepatoma 
tumor-bearing rats (Borner et al., 2018). However, GLP-1 might not be 
the only neuropeptidergic mediator of CACS in the brainstem (see 
Figs. 2–5). 
Prolactin-releasing peptide (PrRP) is also expressed in NTS neurons. 
While GLP-1 is produced by glutamtergic neurons (Zheng et al., 2015), 
PrRP neurons are noradrenergic and belong to the A2 subpopulation in 
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the NTS (Maniscalco et al., 2015; Roland et al., 1999). There is evidence 
for an involvement of PrRP in the control of food intake and energy 
balance. Mice deficient for PrRP or its receptor GPR10 become obese 
and lipidized analogs of PrRP counteract experimentally induced obesity 
(Mochiduki et al., 2010; Gu et al., 2004; Maletínská et al., 2015). 
Accordingly, mice treated with a PrRP-specific antibody show hyper-
phagia (Takayanagi et al., 2008), but no studies investigated the role of 
PrRP in CACS. In addition to a possible involvement in cancer anorexia, 
PrRP might increase glucocorticoid-dependent muscle wasting under 
cancer conditions. 
Stress hormone signalling contributes to cachexia and is triggered via 
neuronal pathways originating in the hindbrain. Projections from the 
NTS mediate hypothalamus-pituitary-adrenal (HPA) axis activation 
involving a stimulation of neurons in the hypothalamic paraventricular 
nucleus (PVN). Under chronic disease conditions (e.g. cancer, chronic 
infection, etc.) HPA axis activation leads to excessive muscle wasting 
(see (Burfeind et al., 2016; van Norren et al., 2017; Braun and Marks, 
2015) for review). PrRP/A2 neurons are synaptically connected to 
neurons of the PVN expressing corticotropin-releasing hormone (CRH) 
(Liposits et al., 1986). Moreover, PrRP and noradrenaline stimulate 
neuronal activity in the PVN and increase ACTH and corticosterone 
plasma levels (Seal et al., 2002; Mera et al., 2006; Cole and Sawchenko, 
2002). Glucocorticoids increase protein breakdown and decrease pro-
tein synthesis (Schakman et al., 2013). The E3 ubiquitin ligase muscle 
RING finger protein-1 (MuRF-1) is one of the mediators of 
glucocorticoid-dependent muscle wasting (Bodine and Baehr, 2014). 
MuRF-1 deficient mice are protected against muscle degradation 
induced by synthetic glucocorticoids (Baehr et al., 2011). Glucocorti-
coids also upregulate the expression of myostatin (Allen and Loh, 2011), 
which inhibits muscle growth and differentiation via MuRF-1 signalling 
(Taylor et al., 2001; Gilson et al., 2007). Muscle protein synthesis de-
pends on the mTOR (mammalian target of rapamycin) pathway (Saxton 
and Sabatini, 2017). Anabolic mTOR signalling is inhibited by the mTOR 
suppressor gene REDD1 (Wang et al., 2006). 
Given their role in energy homeostasis and stress hormone signal-
ling, PrRP neurons may be involved in anorexia, muscle wasting and 
HPA axis activation under cancer conditions. To explore this, we 
knocked down PrRP expression in the NTS of rats using a shRNA gene 
silencing approach. We measured food intake, body weight develop-
ment, muscle mass, corticosterone levels, and markers for muscle pro-
tein degradation and synthesis. 
2. Material and methods 
2.1. Animals and housing conditions 
Male Buffalo rats (Charles River Laboratory, USA) weighing 
410–480 g were single housed in wire-mesh cages. Exposed to a 12-h 
artificial life cycle (lights on at 6:00 a.m.) and a controlled tempera-
ture (21 ± 1∘C), the animals had ad libitum access to standard laboratory 
chow. All animal procedures were approved by the Veterinary Office of 
the Canton of Zurich (license number: 042/2018). 
2.2. PrRP gene knockdown in the NTS by adeno-associated virus 
Capsid 8 adeno-associated viruses (AAV) with a physical titer of 4.1 
× 1012 vg/ml were designed and produced by the Viral Vector Facility at 
the University of Zurich. The control virus encoded four identical non- 
target sequences of short-hairpin RNA (shRNA) under the control of 
the human synapsin-1 promoter hSyn1. The vector used for the knock-
down group induced the expression of four different shRNA constructs 
directed against the PrRP gene, also under the control of hSyn1. In 
addition, both of the vectors’ genomes contained enhanced green fluo-
rescent protein (EGFP) as a reporter gene to allow the confirmation of 
successful transfection and expression of the vectors’ genome in cells of 
the target area. The non-silencing shRNA construct designed for the 
control AAV was 63 base pairs long and did not target any known gene 
(atctcgcttgggcgagagtaagtagtgaagccacagatgtacttactctcgcccaagcgagag). 
The AAV used for the knockdown group contained four different anti- 
PrRP sequences of 22 base pairs (first: tagcagcagcaagcacagaagc, sec-
ond: caagcttagcagcagcaagcac, third: gtctccatggagtgctggtggg, fourth: 
aagtccagtgacatccctcggg). Rats were randomly divided into two different 
experimental groups, one treated with the AAV containing the non- 
silencing shRNA (control-AAV) and the other treated with the AAV 
containing the anti-PrRP shRNA sequences (PrRP-AAV) on day −23. 
2.3. Stereotaxic surgery 
Rats were deeply anaesthetized with a mixture of ketamine (Streuli 
Pharma; Switzerland; Ketanarkon; 40 mg/kg) and medetomidine (Vir-
bac; UK; Medetor; 80 mg/kg) injected intraperitoneally. The animals 
also received the antibiotics enrofloxacin (Bayer; Germany; Baytril; 0.4 
mL/kg; injected subcutaneously) and the analgesic meloxicam (Boeh-
ringer Ingelheim; Germany; Metacam; 1 mg/kg; injected subcutane-
ously). Surgical anaesthesia was confirmed via the loss of toe pinch 
withdrawal reflex. Afterwards, the animals’ heads were shaved and 
fixed to a stereotaxic frame (Stoelting, USA). Body temperature was 
monitored throughout the surgery and a heating pad was used to 
minimize anaesthesia-induced heat loss. Once the head was put in a 
ventroflexed position, a midline incision was made above the occipito- 
atlantal joint and the underlying muscles were retracted. The occipito- 
atlantal membrane was removed in order to expose the area of the 
obex, which was used as a reference point for the stereotactic injection 
into the NTS. A microinfusion pump (World Precision Instrument, USA) 
was assembled into a stereotaxic arm and equipped with a 10 μl glass- 
syringe (Nanofil, World Precision Instrument, USA) and a 35G bev-
elled needle (World Precision Instrument, USA). The needle was moved 
to a position 100 μm caudal and 400 μm lateral to the obex and then 
lowered 600 μm starting from the surface of the brain in order to inject 
into the medial portion of the NTS (mNTS). These injection sites were 
chosen based on the location of PrRP neurons (Roland et al., 1999) and 
correspond to bregma −14.52 mm according to the rat brain atlas by 
Paxinos and Watson (2007). Two μl of AAV were bilaterally infused into 
the mNTS (1 μl per side) at a speed of 0.2 μl per minute. Injection volume 
and speed were controlled with a Micro 4 Microsyringe Pump Controller 
(World Precision Instrument, USA). After infusion was completed, the 
needle was kept at the site of injection for 2 min to prevent reflux. After 
the injection, the retracted muscles and skin were sutured. Anaesthesia 
was reversed with the α2 adrenoceptor antagonist atipamezole hydro-
chloride (Virbac; UK; Revertor; 0.7 mg/kg). For the post-operative care, 
Medetor and Baytril were administered 24 h and 48 h after surgery. 
2.4. Confirmation of adeno-associated virus infection in the NTS 
Before carrying out any of the experiments described below, two 
Buffalo rats were injected with the control virus. After a recovery period 
of three weeks, the animals were euthanized and perfused. The rats were 
anaesthetized with pentobarbital (100 mg/kg, intraperitoneal). Perfu-
sion pressure was generated by gravity (1.5 m hydrostatic pressure). 
Perfusion with phosphate-buffered saline (PBS) was conducted for 2 min 
before fixing the tissues with 4% paraformaldehyde perfusion for 4 min. 
Brains were removed and postfixed in 4% paraformaldehyde for 24 h at 
4 C and transferred to 20% sucrose for overnight cryoprotection. Brains 
were cut in 20 μm thick coronal slices using a cryomicrotome. The 
sections were mounted, air-dried for 7min and rehydrated for 15min in 
PBS. After coverslipping, the slides containing the NTS were analysed 
under a fluorescent microscope (Imager.Z2, Zeiss, Germany) in order to 
identify EGFP expression, which served as an indicator of successful 
transfection. 
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2.5. Cell culture and tumor model 
Morris hepatoma 7777 cells (McA-RH7777, Catalogue No. CRL- 
1601, ATCC, USA) were cultured at 37◦C and 5% CO2, in a media 
(DMEM, Catalogue No. 30–2002, ATCC, USA) supplemented with 10% 
fetal bovine serum and 1% penicillin-streptomycin. Subcultivation was 
performed weekly, before 70% confluence was reached. Petri dishes 
were washed with DMEM to detach adhered cells, which were then 
transferred into a falcon tube and centrifuged at 850 rpm for 10min. The 
resulting cell pellet was resuspended in fresh growth media in a 1:4 
ratio. Tumor induction was performed three weeks after surgery. Cancer 
cells were centrifuged and resuspended in PBS. Once their viability was 
confirmed via the trypan blue exclusion method, 107 viable cells in 250 
μl of PBS were subcutaneously inoculated per rat, between the shoulder 
blades with a 20G needle. To achieve an accurate injection, the rats were 
shortly anaesthetized with isoflurane. The experiment was terminated 
when our criteria defining the humane endpoint for tumor-bearing an-
imals were reached. 
2.6. Monitoring of body weight and food intake 
Body weight and food intake were measured on a daily basis at 10:00 
a.m. during the light phase. Food intake was calculated by subtracting 
the total weight of spilling resistant food hoppers from the weight 
measured on the previous day. 
2.7. Confirmation of PrRP gene knockdown 
PrRP transcripts were measured in all experimental animals at the 
end of the experiment. After the injection of a lethal dosage of pento-
barbital (100 mg/kg, intraperitoneal) rats were decapitated, and the 
brains collected and preserved in dry ice until their storage in the −80∘C 
freezer. In the cryomicrotome (Leica Microsystem, Germany), micro-
punches of the NTS and the primary somatosensory cortex were ob-
tained using a 2 mm micropuncher (Soft Tissue Biopsy Punch, Zivic 
Instruments, USA). The cortex area corresponded to the coordinates 
bregma −1.30 mm, lateral 5 mm and dorsoventral 2 mm according to 
the rat brain atlas (Paxinos and Watson, 2007) and was used as a 
negative control as it lacks PrRP neurons (Roland et al., 1999). 
RNA was extracted and purified from each tissue punch according to 
the manufacturer’s instructions (Reliaprep, Promega, USA) and quan-
tified using the spectrophotometer (NanoDrop, 2000; Thermo Fischer 
Scientific, USA). The extracted RNA was reverse transcribed to cDNA 
using the SensiFAST cDNA Synthesis Kit (Bioline, UK). Fast quantitative 
real-time PCR using pre-designed Taqman probes (Applied Biosystems, 
USA) was performed. Rps18 (Rn01428915) was used as housekeeping 
reference gene to quantify gene expression in the brain tissue. The 
knockdown was analysed using Rn00573653 probe to amplify PrRP 
transcripts. Given that vector-induced inflammation might be associated 
with reduced transgene expression as well as altered neuronal function 
(Ahi et al., 2011), the presence of inflammatory biomarkers in the NTS 
was evaluated using the probes TNF-α (Rn01525859), IL-1β and IL-6 
(probes designed by Dunn-Meynell et al. (2016)). Cortical samples 
were also included in the analysis as negative controls. 
2.8. Gene expression in muscle tissue 
After sacrifice, the left gastrocnemius, anterior tibialis, and soleus 
muscle were dissected, weighed, flash-frozen in liquid nitrogen and 
stored at −80∘C. Skeletal muscle MuRF-1 gene expression was assessed 
using the digital droplet PCR (ddPCR). 30 μl of RNA were isolated from 
15 to 20 mg of muscle tissue, analysed in the spectrophotometer and 
later diluted with nuclease-free water to ensure even concentration (18 
ng/μl) across samples for the conversion into cDNA by reverse tran-
scription. All procedures were performed using the kits described above 
for the preparation of the brain micropunches. The first step of ddPCR 
was droplet generation, which consisted of the samples’ fractioning into 
nanometric oil droplets. For this, 10 μl of cDNA (0.1 ng/l) were com-
bined with 10 μl of ddPCR Supermix and 1 μl of 20× Taqman assay 
(Rn00590197) according to the instructions of the manufacturer 
(QX100 Droplet Generator, BioRad, USA). In order to amplify the sam-
ples’ cDNA, endpoint PCR was performed using the Mastercycler 
(Eppendorf; Germany). QX100 Droplet Reader (BioRad, USA) quantified 
the amount droplets positive for MuRF-1. ddPCR data was analysed with 
QuantaSoft Software. Further analysis of muscle gene expression in 
gastrocnemius was performed by qPCR with GAPDH (Rn01775763) as 
housekeeping reference gene. The following probes were used to assess 
the muscle degradation marker myostatin (Rn00569683), the marker 
for suppression of mTOR REDD1 (Rn01433735) as well as mTOR itself 
(Rn00693900). 
2.9. Measurement of corticosterone 
Blood samples (approx 250 μl) from the lateral tail vein were 
collected by tail nicking one day before tumor cell inoculation (day −1), 
a week afterwards (day 6) and at the end of the experiment (day 21), 
always at 10:00 a.m., i.e. 4 h after light onset. For this, 500 μl EDTA- 
coated tubes, previously prepared with 1 μl of protease inhibitor, were 
employed. Immediately after blood collection, all samples were centri-
fuged at 12,000 rpm and 4∘C for 10 min in order to separate plasma from 
blood cells. Plasma corticosterone levels were measured using the 
DetectX Corticosterone Enzyme Immunoassay Kit (Arbor Assays, USA). 
The ELISA plates were analysed in a microplate reader (Epoch 2, BioTek, 
USA) at 450 nm. 
2.10. Data evaluation and statistical analysis 
All data are expressed as mean ± standard error of the mean. 
Quantitative PCR data were analysed with the delta-delta Ct method, 
which normalizes the cycle threshold values of the gene of interest 
against those of the housekeeping gene. PrRP, TNF-α, IL-1β and IL-6 
expression (relative to Rps18) were calculated and compared between 
PrRP-AAV and control-AAV animals. 
To assess body weight changes associated with CACS, two calcula-
tions were performed. First, body weight before tumor induction (day 
−1) was subtracted from weight at day 13, which corresponded to the 
onset of body weight loss. For the second, body weight on day 13 was 
subtracted from weight before sacrifice (day 20). The latter period 
corresponded to the phase of apparent cachexia. Due to a body weight 
difference between the experimental groups, individual food intake 
values were corrected for body weight (food intake/100 g body weight). 
In addition, average daily food intake per week was calculated for each 
rat over the 3-week period following tumor cell inoculation. 
Unpaired student’s T-test (two-sided) was employed to compare 
differences between two groups. P values were corrected for false dis-
covery rate for multiple tests between two groups. For multiple com-
parisons, a one-way ANOVA or repeated measures one-way ANOVA in 
combination with a Tukey’s multiple comparison test was applied. In all 
statistical tests, a p value lower than 0.05 was considered significant. 
Data analysis was performed using Graphpad Prism 8. 
3. Results 
3.1. Knockdown of PrRP gene expression in the brainstem 
Fig. 1A illustrates the approximate injection sites at the level of the 
NTS. As confirmed by the expression of EGFP, transfection occurred in 
the diffusion field of the AAV, which was spatially restricted to the 
dorsomedial part of the medulla oblongata (1 B). Animals injected with 
PrRP-AAV showed a significant 96 ± 2% knockdown of PrRP gene 
expression compared to animals receiving control-AAV (1C). To exclude 
local inflammatory responses, we assessed expression of TNF-α, IL-1β 
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Fig. 1. PrRP knockdown in the NTS. A) Top view of surgery field illustrating the position of the AAV injection sites. B) Distribution of EGFP expression in the medulla 
oblongata reflecting successful AAV transfection (GR, nucleus gracilis; DVC, dorsal vagal complex; CC, central canal). C) PrRP expression was effectively reduced in 
PrRP-AAV rats. D) AAV injection into the NTS did not affect the local expression of the inflammatory marker IL1-β when compared to expression levels in the cortex. 
E) Body weight development after AAV injection (day −23) under non-tumor conditions. * p ≤ 0.05 Student’s T-test. 
Fig. 2. PrRP knockdown in the NTS attenuated cancer-induced anorexia. A) Mean daily food intake corrected for body weight (BW) was significantly higher in PrRP- 
AAV rats compared to controls during the last week of tumor growth. B) The mean individual food intake averaged across weeks significantly decreased about twice 
as much in control animals compared to PrRP-AAV rats. * p ≤ 0.05; ** p ≤ 0.01 Student’s T-test; different letters indicate significant differences, one-way ANOVA 
with Tukey’s multiple comparison test, p ≤ 0.05. 
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Fig. 3. PrRP knockdown in the NTS attenuated cancer-induced body weight loss. A) Body weight development in PrRP-AVV and control rats after inoculation of 
hepatoma tumor cells. B/C) While both experimental groups showed similar body weight gain during the first two weeks of tumor growth, both groups lost body 
weight in the last week. However, body weight loss was significantly reduced in PrRP-AVV rats. * p ≤ 0.05, Student’s T-test. 
Fig. 4. PrRP knockdown in the NTS attenuated cancer-induced muscle wasting. A) Knockdown of PrRP in the NTS resulted in higher hindlimb muscle mass. B/C) 
Muscle atrophy markers MuRF-1 and myostatin were not affected by the knockdown of PrRP. D/E) mTOR and REDD1 expression tended to be lower in PrRP-AAV 
group. * p ≤ 0.05, Student’s T-test. 
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and IL-6 expression at the injection site in the NTS and in the cerebral 
cortex, which was used as a negative control. In control-AAV and PrRP- 
AAV rats, the three inflammatory markers had similar expression values 
in the NTS and in the cortex (see 1D for IL-1β, TNFα and IL-6 not shown). 
Hence, there was no indication of local inflammation induced by the 
viral vector. Both groups had almost identical average body weight at 
the time point of AAV injection (day −23). After recovery from surgery, 
body weight development started to diverge. At day −1 control rats 
were on average 26 g heavier than PrRP knockdown animals which was 
significant (1 E). 
3.2. Brainstem PrRP contributes to cancer anorexia and body weight loss 
In line with our previous publications (Borner et al., 2017, 2018), 
tumor-bearing rats decreased food intake after inoculation with hepa-
toma cells. When corrected for differences in body weight, food intake of 
PrRP knockdown rats was similar to control rats during the first two 
weeks but significantly higher during the last week of the experiment (2 
A). Daily food intake averaged across each of the three experimental 
weeks progressively and significantly decreased by 42% in the 
control-AAV group whereas PrRP-AAV rats consumed only 20% less in 
the third compared to the first week after tumor cell inoculation (2 B). 
After induction of tumor growth, control and knockdown rats showed a 
similar body weight development during the first two weeks. Control 
rats continued to be heavier (3 A) but this difference in body weight was 
not significant. The average body weight converged mainly because of a 
higher weight loss in the control rats. Between days 0 and 13 both 
groups gained a similar amount of weight. While both groups lost weight 
during the last week, the average body weight loss in controls was 
significantly higher and twice as much as in PrRP-AAV rats during week 
3 (3 B–C). Hence PrRP knockdown rats were partly protected against 
cachexia. 
3.3. Brainstem PrRP mediates cancer-induced muscle wasting 
Disruption of hindbrain PrRP signalling resulted in higher muscle 
mass at study end. Gastrocnemius and total muscle mass was signifi-
cantly higher in PrRP-AVV rats compared to controls while we did not 
observe significant differences in soleus and tibialis muscle weights (4 
A). Despite this effect of PrRP gene silencing on muscle wasting there 
were no significant differences in gene expression of MuRF-1, mTOR, 
myostatin, and REDD1 between the groups (4 B-E). However, REDD1 
and mTOR expression tended to be lower in PrRP-AAV rats (student’s T- 
test, p = 0.105 and p = 0.162, respectively). Interestingly, corticoste-
rone levels were increased significantly at day 6 after tumor cell inoc-
ulation in both groups. However, only in PrRP knockdown rats did the 
elevated corticosterone levels return to the baseline level measured 
before tumor growth. In the control group, corticosterone appeared to 
remain elevated until the end of the experiment, although the levels at 
day 21 did not reach significance when compared to baseline values (5 
A). Differences in tumor burden did not seem to account for any of the 
observed differences in the experimental parameters because average 
tumor weights were almost identical in both groups (5 B). 
4. Discussion 
This study sought to determine whether PrRP contributes to cancer 
anorexia and body weight loss in a rat model for AP/NTS dependent 
CACS. (Borner et al., 2017). We developed a highly effective 
shRNA/AAV gene silencing approach to knockdown PrRP expression in 
the NTS. We analysed changes in body weight and food intake, muscle 
mass, stress hormone levels, and muscle markers reflecting muscle 
protein degradation and synthesis. Overall, our findings indicate that 
genetic disruption of the PrRP signalling in the NTS significantly ame-
liorates CACS. 
PrRP gene silencing was remarkably effective, which appears to be 
due to the AAV’s highly effective plasmid design with the inclusion of 
four different shRNA sequences (Taxman et al., 2010). There were no 
Fig. 5. Corticosterone levels and tumor size. A) Both groups showed increased corticosterone levels at day 6 after tumor cell inoculation compared to baseline levels 
(day −1). In PrRP-AAV rats corticosterone levels significantly decreased between day 6 and day 21 and returned to baseline levels. B) Tumor weights were not 
affected by PrRP knockdown. Different letters indicate significant intra-group differences; repeated measures one-way ANOVA with Tukey’s multiple comparison 
test, p ≤ 0.05 (A). Student’s T-test (B). 
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indications of local inflammation, which is in favor of a high knockdown 
efficiency (Nayak and Herzog, 2010) without the risk of confounding 
side effects. As confirmed histologically, the transfection was restricted 
to the dorsomedial medulla oblongata covering the area of the NTS 
where PrRP expressing neurons are located (Lee et al., 2000; Roland 
et al., 1999). Therefore, it is unlikely that our AAV knockdown approach 
affected PrRP expression in other brain areas, although we did not 
specifically analyze this. 
The PrRP knockdown considerably attenuated body weight loss 
during the phase of cachexia even though the absolute body weight was 
not different between the groups at the end of the experiment. This was 
obviously due to the higher body weight gain of the AAV-control rats 
before tumor cell inoculation. The attenuation of cachexia in the PrRP- 
AVV group is reflected by a mitigation of tumor-induced body weight 
loss rather than by a difference in absolute body weight per se. Pre-
sumably, the absolute body weight of the tumor-bearing controls would 
decrease below the level of the knockdown rats at a later stage, but the 
experimental duration in cancer models is limited because of rapid 
tumor progression and the requirement to establish humane endpoints. 
While there is no clear definition for cancer cachexia in animal models, 
weight loss rather than absolute body weight is a key parameter in the 
definition of cachexia in humans (Fearon et al., 2011; Vanhoutte et al., 
2016). We therefore believe it is justified to interpret the attenuation of 
body weight loss together with our other findings as an amelioration of 
CACS by the knockdown of PrRP. It appears plausible based on our 
findings that PrRP acts as a causal mediator of CACS, but we cannot rule 
out the possibility that the knockdown of PrRP counteracts CACS 
without direct involvement in the underlying pathological processes. 
However, this would imply that the knockdown per se induced an 
anabolic effect when CACS developed. We did not specifically control 
for this, but the similar body weight gain of PrRP-AAV and control-AAV 
for a period of 13 days before the onset of CACS does not support the 
idea of an anabolic effect caused by the knockdown. 
The hepatoma tumor model is characterized by anorexia, which 
parallels body weight loss. In our previous studies we pair-fed non- 
tumor-bearing and tumor-bearing rats and compared body weight 
development to ad libitum fed controls (Borner et al., 2017). At a similar 
terminal time point as in our current study, around half of the 
cancer-induced body weight loss appeared to be explained by decreased 
food intake because pair-fed rats did not lose weight to the same extent 
as tumor-bearing animals. Therefore, the attenuation of cancer anorexia 
by PrRP knockdown presumably contributed to body weight loss, but we 
did not reconfirm this in our current studies. Notably, food restriction 
might lead to the development of food-seeking behaviour and other 
confounding factors in pair-fed animals (e.g. changes in energy expen-
diture) that are difficult to control for. 
PrRP-AAV rats had higher gastrocnemius and total hind limb muscle 
mass than the controls. Similar to our previous studies involving a 
knockdown of GLP-1 in the NTS (Borner et al., 2018), we did not observe 
significant changes in the soleus and tibialis muscle mass, which might 
be less susceptible to cachexia. The effect of PrRP knockdown on 
gastrocnemius muscle mass was not paralleled by a change in MuRF-1 
mRNA levels. In C26 tumor-bearing mice, MuRF-1 is overexpressed 20 
days after tumor induction (Villars et al., 2017), but not at day 15 or 
earlier time points. Therefore we analysed MuRF-1 expression at the end 
of the experiment which appeared to be the most likely time point to 
observe changes in expression. While we cannot rule out the possibility 
that MuRF-1 expression might have been altered earlier during the 
experiment, changes in MurF-1 expression do not seem to contribute to 
PrRP-dependent muscle wasting in this model. We also analysed the 
expression of other markers known to be involved in muscle wasting. 
Myostatin is an extracellular signalling peptide that negatively controls 
myogenesis via different intracellular pathways (Rodriguez et al., 2014). 
Knockdown of myostatin expression by RNA interference attenuates 
cancer-dependent muscle wasting (Liu et al., 2008). Given the similar 
myostatin expression in PrRP-AAV rats and controls, knockdown of 
PrRP does not seem to act through increased myostatin signalling at 
least with respect to the transcriptional level. Interestingly, we observed 
tendencies of reduced expression levels for mTOR and REDD1 in 
PrRP-AVV rats compared to controls, although the differences did not 
reach statistical significance. While some studies demonstrated reduced 
mTOR signalling in cancer cachexia (White et al., 2011; Puppa et al., 
2014; Chen et al., 2016), other studies support the idea that mTOR in-
hibition counteracts cachexia by modulating mTOR-dependent auto-
phagy (Pigna et al., 2016; Zhao et al., 2015). Notably, mTOR pathway 
activity is not only reflected by mTOR expression, but also by mTOR 
phosphorylation and the activation of the mTOR receptor complex 1 
(mTORC1), which we did not directly analyze. REDD1 functions as an 
inhibitor of the mTORC1 (Deyoung et al., 2008). A reduced expression 
of REDD1 in PrRP-AAV rats might reflect increased mTOR pathway 
activity. Taken together, our findings may suggest some alterations of 
the mTOR pathway in response to PrRP knockdown, but it remains to be 
explored if this results in a significant change of downstream signalling 
processes. 
At day 6 after tumor cell inoculation, corticosterone levels were 
elevated in both groups compared to baseline values. While in control- 
AAV rats corticosterone concentrations remained at a similar level on 
day 21, corticosterone returned to baseline levels in PrRP-AAV rats. This 
finding points to a PrRP-dependent increase in stress hormone signalling 
during cancer cachexia. It is interesting that PrRP knockdown did not 
prevent the early rise in corticosterone. Presumably, the mechanisms 
contributing to HPA axis activation during the course of tumor growth 
involve diverse pathways that are independent of PrRP. Injection of 
tumor cells per se and the host reactions during the initial phase may 
trigger different stressors than those caused by the increasing tumor 
burden at later stages. 
The humoral mediators of CACS in hepatoma tumor bearing rats 
have not yet been clearly determined. While the typical cytokines 
contributing to CACS are not elevated in this tumor model (Ruud and 
Blomqvist, 2007), we previously reported highly elevated levels of 
GDF-15 (Borner et al., 2017), which acts via the recently discovered 
receptor GFRAL in the AP/NTS region (Emmerson et al., 2017). Thus 
PrRP expressing NTS neurons are well-positioned to be directly or 
indirectly activated by GDF15 or other humoral mediators of CACS 
acting on the AP/NTS region. Immunohistological studies detecting 
cancer-induced neuronal activation (c-Fos), and PrRP and GFRAL 
expression might help to shed more light on the cellular responses and 
neuronal phenotypes. Whether decreased corticosterone levels 
following PrRP knockdown contributed to the mitigation of CACS in our 
model requires further investigation directly targeting glucocorticoid 
signalling. Muscle specific knockout of the glucocorticoid receptor 
resulted in a 70% decrease of muscle wasting in mice bearing Lewis lung 
cancer tumors (Braun et al., 2013), which highlights the importance of 
stress hormone signalling in CACS. 
To assess the effect of PrRP knockdown under non-pathological 
conditions, we monitored body weight development prior to tumor in-
duction. Disruption of PrRP gene expression resulted in diverging 
weight gain and significantly lower body weight three weeks after AAV 
injections. This finding appears unexpected as most literature describes 
PrRP as an anorexigenic hormone with respect to its action on food 
intake (see (Tachibana and Sakamoto, 2014) for review). Blocking of 
PrRP results in hyperphagia and increased body weight. Moreover, 
PrRP-deficient mice and WT mice that received an injection of an 
anti-PrRP antibody into the lateral cerebral ventricle develop late-onset 
obesity (Takayanagi et al., 2008). However, these findings should be 
compared with caution across the studies because there are relevant 
methodological differences. While we only targeted PrRP expressing 
cells in the NTS, Takayanagi et al. used mice with a global knockdown 
affecting all PrRP-expressing neuronal populations, including those in 
the dorsomedial hypothalamus and the ventrolateral medulla (Takaya-
nagi et al., 2008). Similarly, intracerebroventricular injection of the 
PrRP neutralizing antibody is likely to block central PrRP actions in a 
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different manner than our specific knockdown in the NTS. Irrespective 
of these considerations, the lower body weight gain induced by PrRP 
knockdown under non-tumor conditions appears surprising given its 
anti-cachectic effect during tumor growth. It was beyond the scope of 
our studies to investigate the effect of PrRP knockdown in the NTS under 
non-pathological conditions in more detail, but future studies using a 
similar approach should focus on this interesting finding. Given the role 
of A2 neurons in physiological satiation it would also be interesting to 
elucidate whether PrRP and noradrenaline might have different roles in 
physiological and pathological anorexia. With respect to a possible 
treatment approach against CACS, any effect that reduces basal body 
weight or body weight gain would be undesired. The reduction in body 
weight gain was not apparent anymore during the pre-cachectic phase 
on days 0–13 after tumor cell inoculation. Therefore, it is questionable 
whether it might represent a relevant limitation during a longer lasting 
therapeutic approach targeting PrRP signalling because the effect of the 
knockdown did not appear to be progressive. 
In summary, this is the first study to explore the involvement of 
brainstem derived PrRP in the pathology of CACS. Our experiments 
point to a possible role of PrRP as a neuropeptide mediator of CACS. 
Disrupting PrRP signalling might be therapeutically exploited to 
ameliorate CACS-related symptoms and possibly HPA axis activation 
under cancer conditions. Given the recently demonstrated involvement 
of hindbrain GLP-1 in CACS (Borner et al., 2018), it would be interesting 
to investigate if there is an interaction between these neuropeptides, i.e. 
whether their actions are interdependent or if they function as mediators 
in discrete pathways originating in the brainstem. Future studies should 
also shed more light on the possible upstream and downstream mech-
anisms involved in PrRP-dependent CACS and validate our findings in 
different cancer models. 
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